IP Library Granted Patent US 9,822,380
Granted Patent B2
US 9,822,380 · App. 14/515,817 · Granted Nov 21, 2017

Nucleic acid for treatment or prevention of immunodeficiency virus infection

Inventors: Hideto Chono (Otsu, JP); Kazuya Matsumoto (Otsu, JP); Junichi Mineno (Otsu, JP); Ikunoshin Kato (Otsu, JP)
Assignee: TAKARA BIO INC.
C12N15/86A61K31/7088A61K35/17A61K38/465C07K14/4702C12N5/0636C12N9/22C12N15/85A61K38/00A61K48/00C12N2510/00C12N2830/002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,822,380
App. No.
14/515,817
Granted
Nov 21, 2017
Kind
B2
Abstract

A nucleic acid comprising a transcription regulation sequence whose transcription is induced by a trans-acting factor of a human immunodeficiency virus and a gene encoding a polypeptide having an endoribonuclease activity specific to single-stranded RNA, wherein the gene is located in such a position that the expression of the gene can be regulated by the transcription regulation sequence; a method for production of a cell showing an inhibited replication of a human immunodeficiency virus therein, the method comprising the step of introducing the nucleic acid into a cell; and a method for treatment or prevention of a human immunodeficiency virus infection.

Claims (6)

1. An isolated cell comprising a nucleic acid comprising a long terminal repeat (LTR) of human immunodeficiency virus (HIV) with which transcription is induced by Tat protein and/or Rev protein of human immunodeficiency virus; and a gene comprising the nucleotide sequence as set forth in SEQ ID NO: 3 encoding a naturally occurring E. coli MazF protein, which specifically cleaves a sequence 5′-A/CA-3′ in a single-stranded RNA, wherein the gene is placed downstream of said LTR such that its expression can be controlled by said LTR.

2. The isolated cell of claim 1 , wherein the cells is a T cell or a T cell precursor.

3. A method for producing the cell of claim 1 , the method comprising the step of introducing a nucleic acid into an isolated cell, wherein the nucleic acid comprises a long terminal repeat (LTR) of human immunodeficiency virus (HIV) with which transcription is induced by Tat protein and/or Rev protein of human immunodeficiency virus; and a gene comprising the nucleotide sequence as set forth in SEQ ID NO: 3 encoding a naturally occurring E. coli MazF protein, which specifically cleaves a sequence 5′-A/CA-3′ in a single-stranded RNA, wherein the gene is placed downstream of said LTR such that its expression can be controlled by said LTR.

4. The method of claim 3 , wherein the nucleic acid is incorporated into a virus vector.

5. The method of claim 4 , wherein the nucleic acid is incorporated into a retrovirus vector.

6. The method of claim 3 , wherein the cell is a T cell or a T cell precursor.

Assignments (2)
CHANGE OF ADDRESS Recorded Jun 29, 2016
From: TAKARA BIO INC.
To: TAKARA BIO INC.
Reel/Frame 039206/0281 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2015
From: CHONO, HIDETO; MATSUMOTO, KAZUYA; MINENO, JUNICHI; KATO, IKUNOSHIN
To: TAKARA BIO INC.
Reel/Frame 035483/0937 →
Priority Claims (2)
JP 2005-236160 · Aug 16, 2005 · national
JP 2006-140243 · May 19, 2006 · national
Continuity (2)
Division 12064185
Related Publication 20150037300A1 · Feb 5, 2015